Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia
{{output}}
Mutations in the RAS/MAPK signaling pathway are recurrent in acute myeloid leukemia (AML), primarily involving NRAS and KRAS. In contrast, mutations in the gene encoding an effector protein, BRAF, occur at relatively lower frequencies in AML and are associated... ...
